睾酮替代疗法与心血管后果之间的关系:30 项随机对照试验的荟萃分析。

IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
{"title":"睾酮替代疗法与心血管后果之间的关系:30 项随机对照试验的荟萃分析。","authors":"","doi":"10.1016/j.pcad.2024.04.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>The Cardiovascular safety of testosterone replacement therapy (TRT) among men with </span>hypogonadism<span> is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials.</span></p></div><div><h3>Methods</h3><p>We performed a systematic literature search on PubMed, EMBASE, and <span><span>Clinicaltrial.gov</span><svg><path></path></svg></span><span> for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023.</span></p></div><div><h3>Results</h3><p>A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77–1.62), <em>P</em> = 0.55), stroke (OR, 1.01 (95%CI: 0.68–1.51), <em>P</em> = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76–1.45), <em>P</em> = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76–1.17), <em>P</em> = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65–1.15), <em>P</em> = 0.31) was comparable between TRT and placebo groups.</p></div><div><h3>Conclusion</h3><p>Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.</p></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials\",\"authors\":\"\",\"doi\":\"10.1016/j.pcad.2024.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>The Cardiovascular safety of testosterone replacement therapy (TRT) among men with </span>hypogonadism<span> is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials.</span></p></div><div><h3>Methods</h3><p>We performed a systematic literature search on PubMed, EMBASE, and <span><span>Clinicaltrial.gov</span><svg><path></path></svg></span><span> for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023.</span></p></div><div><h3>Results</h3><p>A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77–1.62), <em>P</em> = 0.55), stroke (OR, 1.01 (95%CI: 0.68–1.51), <em>P</em> = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76–1.45), <em>P</em> = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76–1.17), <em>P</em> = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65–1.15), <em>P</em> = 0.31) was comparable between TRT and placebo groups.</p></div><div><h3>Conclusion</h3><p>Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.</p></div>\",\"PeriodicalId\":21156,\"journal\":{\"name\":\"Progress in cardiovascular diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in cardiovascular diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0033062024000550\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in cardiovascular diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0033062024000550","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景睾酮替代疗法(TRT)对性腺功能减退症男性患者的心血管安全性迄今尚未得到很好的证实。因此,我们试图通过最近发表的所有随机对照试验来评估接受睾酮治疗的患者的心血管疾病(CVD)预后。方法我们在PubMed、EMBASE和Clinicaltrial.gov上进行了系统的文献检索,以查找从开始到2023年9月30日的相关随机对照试验(RCT)。平均年龄为 61.61 岁至 61.82 岁。对主要和次要结果的汇总分析显示,任何心血管疾病事件(OR,1.12(95%CI:0.77-1.62),P = 0.55)、中风(OR,1.01(95%CI:0.68-1.51),P = 0.94)、心肌梗死(OR,1.05(95%CI:0.76-1.45),P = 0.77)、全因死亡率(OR,0.94(95%CI:0.结论我们的分析表明,对于性腺功能减退症患者,睾酮替代疗法不会增加心血管疾病风险和全因死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials

Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials

Background

The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials.

Methods

We performed a systematic literature search on PubMed, EMBASE, and Clinicaltrial.gov for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023.

Results

A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77–1.62), P = 0.55), stroke (OR, 1.01 (95%CI: 0.68–1.51), P = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76–1.45), P = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76–1.17), P = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65–1.15), P = 0.31) was comparable between TRT and placebo groups.

Conclusion

Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Progress in cardiovascular diseases
Progress in cardiovascular diseases 医学-心血管系统
CiteScore
10.90
自引率
6.60%
发文量
98
审稿时长
7 days
期刊介绍: Progress in Cardiovascular Diseases provides comprehensive coverage of a single topic related to heart and circulatory disorders in each issue. Some issues include special articles, definitive reviews that capture the state of the art in the management of particular clinical problems in cardiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信